BioSight
Companies
Jade Biosciences, Inc. logo

JBIO

NASDAQWALTHAM, MA
Jade Biosciences, Inc.

Jade Biosciences is a clinical-stage biopharmaceutical company developing monoclonal antibody therapies to treat autoimmune diseases. Its lead candidate, JADE101, targets APRIL to treat IgA nephropathy and entered Phase 1 testing in 2025, with Phase 2 planned for mid-2026; the company also has JADE201 (targeting BAFF-R for multiple autoimmune disorders) and JADE301 in earlier development. Jade's approach focuses on improving upon existing therapies through better dosing schedules, extended half-lives using YTE technology, and enhanced potency compared to competing candidates.

Price history not yet available for JBIO.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar